BR112022011323A2 - Anticorpo biespecífico anti-antígeno de maturação de célula b (bcma)/anti-4-1bb ou um fragmento de ligação ao antígeno do mesmo, e composição farmacêutica para prevenção ou tratamento de uma doença relacionada ao bcma, 4-1bb ou ambos - Google Patents

Anticorpo biespecífico anti-antígeno de maturação de célula b (bcma)/anti-4-1bb ou um fragmento de ligação ao antígeno do mesmo, e composição farmacêutica para prevenção ou tratamento de uma doença relacionada ao bcma, 4-1bb ou ambos

Info

Publication number
BR112022011323A2
BR112022011323A2 BR112022011323A BR112022011323A BR112022011323A2 BR 112022011323 A2 BR112022011323 A2 BR 112022011323A2 BR 112022011323 A BR112022011323 A BR 112022011323A BR 112022011323 A BR112022011323 A BR 112022011323A BR 112022011323 A2 BR112022011323 A2 BR 112022011323A2
Authority
BR
Brazil
Prior art keywords
bcma
antigen
antibody
binding fragment
cell maturation
Prior art date
Application number
BR112022011323A
Other languages
English (en)
Inventor
Jin Park Kyung
Soon Lee Yang
Yi Lim Sae
Jin Chung Hye
Su Park Kyeong
Gyu Son Yong
Gyu Seon Seong
Jun Son Won
Jung Kim Eun
Hyun EOM Jae
Jung Jung Ui
Ji Park Min
Hyeon Hong Jung
Original Assignee
Abl Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/KR2019/018357 external-priority patent/WO2021132746A1/en
Application filed by Abl Bio Inc filed Critical Abl Bio Inc
Publication of BR112022011323A2 publication Critical patent/BR112022011323A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

ANTICORPO BIESPECÍFICO ANTI-ANTÍGENO DE MATURAÇÃO DE CÉLULA B (BCMA)/ANTI-4-1BB OU UM FRAGMENTO DE LIGAÇÃO AO ANTÍGENO DO MESMO, E COMPOSIÇÃO FARMACÊUTICA PARA PREVENÇÃO OU TRATAMENTO DE UMA DOENÇA RELACIONADA AO BCMA, 4-1BB OU AMBOS. Trata-se de anticorpo biespecífico anti-antígeno de maturação de célula B (BCMA)/anti-4-1BB ou um fragmento de ligação ao antígeno do mesmo e uso do mesmo. O anticorpo biespecífico ou um fragmento de ligação ao antígeno do mesmo pode ter alta afinidade de ligação com ambas dentre uma proteína de BCMA e uma proteína de 4-1BB, e pode ser usado de maneira eficaz para prevenir ou tratar uma doença relacionada ao BCMA, 4-1BB ou ambos (por exemplo, câncer).
BR112022011323A 2019-12-10 2020-12-10 Anticorpo biespecífico anti-antígeno de maturação de célula b (bcma)/anti-4-1bb ou um fragmento de ligação ao antígeno do mesmo, e composição farmacêutica para prevenção ou tratamento de uma doença relacionada ao bcma, 4-1bb ou ambos BR112022011323A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945965P 2019-12-10 2019-12-10
PCT/KR2019/018357 WO2021132746A1 (en) 2019-12-24 2019-12-24 Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
PCT/KR2020/018029 WO2021118246A1 (en) 2019-12-10 2020-12-10 Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112022011323A2 true BR112022011323A2 (pt) 2022-08-23

Family

ID=76330699

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011323A BR112022011323A2 (pt) 2019-12-10 2020-12-10 Anticorpo biespecífico anti-antígeno de maturação de célula b (bcma)/anti-4-1bb ou um fragmento de ligação ao antígeno do mesmo, e composição farmacêutica para prevenção ou tratamento de uma doença relacionada ao bcma, 4-1bb ou ambos

Country Status (9)

Country Link
US (1) US20230051266A1 (pt)
EP (1) EP4048700A4 (pt)
JP (1) JP2023506162A (pt)
KR (1) KR20220110753A (pt)
CN (1) CN114829405A (pt)
AU (1) AU2020400801A1 (pt)
BR (1) BR112022011323A2 (pt)
CA (1) CA3160765A1 (pt)
WO (1) WO2021118246A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242247B2 (en) * 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3131927B8 (en) * 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
CA2995754A1 (en) * 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
EP3464362B1 (en) * 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses

Also Published As

Publication number Publication date
US20230051266A1 (en) 2023-02-16
WO2021118246A1 (en) 2021-06-17
KR20220110753A (ko) 2022-08-09
AU2020400801A1 (en) 2022-07-07
CN114829405A (zh) 2022-07-29
CA3160765A1 (en) 2021-06-17
EP4048700A1 (en) 2022-08-31
JP2023506162A (ja) 2023-02-15
EP4048700A4 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
EA202092460A1 (ru) Антитела к ox40 и способы применения
BR112019007267A2 (pt) anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes
BR112016013338A2 (pt) anticorpo pd-1, fragmento de ligação do antígeno do mesmo e uso médico do mesmo
MX2021005708A (es) Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
CR20200465A (es) Agentes anticuerpos anti-cd25
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
BR112012007365A2 (pt) proteínas de ligação à il-1
BR112017026189A2 (pt) tratamento de câncer através do bloqueio combinado das vias de sinalização de pd-1 e cxcr4
MX2022003249A (es) Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso.
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
MX2021004588A (es) Anticuerpo anti-cldn18.2 y sus usos.
BR112013028779B8 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
BR112016003369A2 (pt) diacorpos monovalentes biespecíficos, diacorpos fc monovalentes biespecíficos, composição farmacêutica, uso da composição farmacêutica, célula que expressa uma cadeia de polipeptídeo de quaisquer dos diacorpos monovalentes biespecíficos, polinucleotídeo que codifica o polipeptídeo, e célula que expressa um anticorpo ou uma porção de polipeptídeo ou fragmento da mesma
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
UA95068C2 (uk) Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
MX2021000399A (es) Moleculas de anticuerpo que se unen a cd137 y ox40.
WO2019028182A3 (en) TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
EA202090265A1 (ru) Композиции, способы и/или наборы, содержащие рекомбинантный внеклеточный домен cd38 человека
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
WO2021227307A8 (zh) 抗cd73抗体及其用途
MX2021011715A (es) Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención.
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo